When seniors hit the Medicare Part D donut hole, they don't switch to less expensive brands or even cheaper generics, a new Harvard Medical School/CVS Caremark study found. They stop taking meds altogether. Release
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments